Channeling the ire of constituents and drawing from personal experience, senators chastised drug company executives Tuesday over the high cost of prescription medications, while the CEOs warned that government price controls could stifle breakthroughs on diseases like Alzheimer's.
The Senate Finance Committee hearing marked the first time lawmakers have called the industry's top executives to account for rising prices, which are a drain on Medicare and Medicaid and a burden to millions of Americans. The extraordinary public accounting was a sign that Congress and the White House are moving toward legislation this year to curb costs.
Sen. Johnny Isakson, R-Ga., who has Parkinson's, said the cost of one of his longtime medications had jumped by $90 when he went to refill it recently. "I can't explain it," said Isakson, who credits prescription drugs for allowing him to keep working. He started making calls and found a whole range of prices for the medication.
The second-ranking Senate Republican, John Cornyn of Texas, expressed disbelief that Humira, a blockbuster drug for immune system conditions from AbbVie, is protected by more than 130 patents that cumulatively translate to decades of roadblocks for generic competitors. AbbVie CEO Richard Gonzalez responded that each new FDA-approved use of the drug represents an investment by the company in research, even if the medication is the same.
"At some point that patent has to end so that the patient can get access to that drug at much cheaper cost," Cronyn said.
Drug costs are squeezing Americans in a number of ways: New medicines for cancer and other diseases often launch with prices exceeding $100,000 per year even as employers are shifting more pharmacy costs onto workers. Less expensive drugs for common ailments like diabetes and asthma often see price hikes of around 10 percent annually. Meanwhile, some drugmakers have been buying up once-cheap medicines and hiking prices by 1,000 percent or more.
The pharmaceutical executives expressed a general desire to lower costs for patients but made no firm commitments. Merck CEO Kenneth Frazier warned that "outrageous solutions" could sacrifice industry innovation. He said lung cancer patients in the United Kingdom are still waiting for a drug available here that can cut deaths in half among those newly diagnosed. Sanofi CEO Olivier Brandicourt said using government "price controls" would not be enough to make medicines affordable.
Politics
Senators seemed to be looking for a balance between protecting innovation and closing off legal and policy loopholes that have enabled savvy companies to game the markets.
New Jersey Democrat Bob Menendez, considered an ally of the industry, delivered what he called a friendly warning: "If you don't undertake meaningful action to reduce pharmaceutical costs, policymakers are going to do it for you."
Committee Chairman Chuck Grassley, R-Iowa, said Congress intends to respond to the drug price problem in a "measured and effective way" and he is planning to question other industry actors including health insurance companies and middlemen called pharmacy benefit managers.
The CEOs said drug development is a risky and costly undertaking and that prices reflect investment in research and development. But under questioning from Grassley, they also acknowledged other factors affecting how they set prices, including public perception and what Medicare and Medicaid pay.
In addition to Merck, Sanofi and AbbVie, other companies represented at the hearing included AstraZeneca, which makes the cholesterol drug Crestor, Bristol-Myers Squibb, maker of the blood thinner Eliquis; Johnson & Johnson, maker of Xarelto to prevent blood clots; and Pfizer, maker of Lyrica for nerve pain.
"All you who are here are here because the way you've been doing business is unacceptable and unsustainable," ranking Democrat Ron Wyden of Oregon told the CEOs.
Democrats say it's time for Medicare to leverage its purchasing power and directly negotiate prices with the industry, a step most Republicans oppose.
The pharmaceutical industry is one of the most powerful lobbies in Washington. Drugmakers' top lobbying arm, the Pharmaceutical Research and Manufacturers of America, spent a record $27.9 million last year to sway federal decision-makers, according to records tallied by the nonprofit Center for Responsive Politics.
But Tuesday's hearing seemed to mark a change in direction. President Donald Trump's recurring blasts at drugmakers appear to be closer to finding a pathway to legislation.
Drugmakers pointed a finger at other industry players. Rebates paid to pharmacy benefit managers help assure favorable treatment for a medication on an insurer's list of covered drugs and help keep premiums lower. But the rebates are not passed on to consumers who use the particular medication, and they can face high copays based on the drug's list price, not the discounted one.
The companies offered solutions of their own, some of which echo proposals from the administration or lawmakers. Among them:
— Allow patients to share in rebates when they buy their medication, proposed by the Trump administration.
— Place a hard limit on cost-sharing and copays for Medicare beneficiaries in the popular Part D prescription program, supported by Wyden.
— Make greater use of value-based contracts that tie payments to how well a medication works.
— Promote the introduction of lower-cost generics and biosimilars, competition that brand manufacturers are often accused of impeding.
